D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05591677 |
Recruitment Status :
Recruiting
First Posted : October 24, 2022
Last Update Posted : January 22, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The goal of this clinical trial is to investigate if the drug D-Cycloserine (DCS) improves the antidepressant effects of Intermittent Theta Burst Stimulation (iTBS), a non-invasive brain stimulation therapy, in patients with Major Depressive Disorder (MDD). The main questions it aims to answer are:
- Whether taking DCS prior to iTBS therapy will be more effective in improving depressive symptoms than iTBS therapy alone.
- Compare the effect of DCS 100mg/day versus 50mg/day on depressive symptoms.
- Test the safety and tolerability of DCS. Participants will take either 50mg DCS per day, 100mg DCS or placebo prior to each iTBS treatment session. iTBS treatment will be administered daily, 5 days a week for 4 weeks. Clinical measures will be conducted at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Major Depressive Disorder | Drug: D-Cycloserine Device: Intermittent Theta Burst Stimulation | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 180 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression: A Multi-Site, Randomised, Placebo-Controlled Trial (COGENT) |
Actual Study Start Date : | April 21, 2023 |
Estimated Primary Completion Date : | December 2024 |
Estimated Study Completion Date : | December 2024 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Active iTBS + active DCS 50mg/day
Active iTBS (600 pulses), 5 days/week x 4 weeks + active DCS 50mg/day x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
|
Drug: D-Cycloserine
D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time. Device: Intermittent Theta Burst Stimulation Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD. |
Active Comparator: Active iTBS + active DCS 100mg/day
Active iTBS (600 pulses), 5 days/week x 4 weeks + active DCS 100mg/day x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
|
Drug: D-Cycloserine
D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time. Device: Intermittent Theta Burst Stimulation Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD. |
Placebo Comparator: Active iTBS + placebo
Active iTBS (600 pulses), 5 days/week x 4 weeks + placebo x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
|
Device: Intermittent Theta Burst Stimulation
Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD. |
- Rate of treatment response as per Montgomery Åsberg Depression Rating Scale (MADRS) [ Time Frame: Determined at Week 4 (primary study endpoint) ]
Clinical treatment response defined as >/= 50% reduction in MADRS scores from baseline to primary study endpoint.
Clinician-administered depression rating scale. The overall score ranges from 0 - 60. Cutoff points are 0-6 = normal, 7-9 = mild depression, 20-34 = moderate depression, >34 = severe depression.
- Change in Montgomery Åsberg Depression Rating Scale (MADRS) [ Time Frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment. ]Clinician-administered depression rating scale. The overall score ranges from 0 - 60. Cutoff points are 0-6 = normal, 7-9 = mild depression, 20-34 = moderate depression, >34 = severe depression.
- Change in Clinical Global Impression (CGI) [ Time Frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment. ]Clinician assessment of overall illness severity and global functioning. The CGI-Severity scale is clinician rated from 1-7 representing 'Not at all ill' to 'Severely ill'. The CGI-Improvement scale is also rated 1-7, representing the range between 'Very much improved' and 'Very much worse'.
- Change in Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR) [ Time Frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment. ]Self-reported symptom rating scale for depression severity. Severity of depression can be judged based on the total score. 1-5 = No depression 6-10 = Mild depression 11-15 = Moderate depression 16-20 = Severe depression 21-27 = Very severe depression.
- Beck's Anxiety Inventory (BAI) [ Time Frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment. ]Self-reported symptom rating scale for anxiety severity. The score range is 0-63. A total score of 0-7 is considered minimal range, 8-15 is mild, 16-25 is moderate, and 26-63 is severe.
- International Trauma Questionnaire (ITQ) [ Time Frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment. ]Self-reported symptom rating of trauma-related symptoms and their severity. All ITQ items are answered on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Extremely).
- Beck's Scale for Suicide Ideation (BSS) [ Time Frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment. ]Self-reported symptom rating scale for suicidal ideation. Scores range from 0 to 38, a higher score indicating a higher level of suicide ideation.
- Change in World Health Organization Quality of Life (WHOQOL-BREF) [ Time Frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment. ]Self-reported rating scale of quality of life. Domains scores are calculated to range from 0-20 and scaled in a positive direction (ie. higher scores denote higher quality of life).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of major depressive episode (MDE), in accordance with the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5), in the context of unipolar major depressive disorder or bipolar affective disorder.
- 18 years or older in age.
- Treatment resistant depression at Stage II of the Thase and Rush classification.56
- Baseline Montgomery Åsberg Depression Rating Scale score of ≥ 20 (moderate-to-severe depression severity).57,58
- No increase or initiation of new antidepressant therapy in the four weeks prior to screening.
- Demonstrated capacity to give informed consent.
Exclusion Criteria:
- Inability to provide informed consent.
- Medically unstable patients at the discretion of the investigator.
- Concomitant neurological disorder or a history of a seizure disorder.
- Participants who are pregnant.
- Current substance use meeting DSM-5 criteria for substance use disorder.
- Per DSM-5, had ever met diagnostic criteria for schizophrenia, schizoaffective disorder, schizophreniform disorder or delusional disorder as assessed by the Mini-International Neuropsychiatric Interview (MINI) at the time of screening.
- Diagnosis of any other mental disorder that is the participant's primary diagnosis or main mental health syndrome of concern at the time of screening, which may significantly affect psychiatric status and assessed as likely to impact trial participation, in the clinical judgement of the investigator.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05591677
Contact: Kaila Bianco | +61 3 9076 6564 | tms-trials@monash.edu | |
Contact: Violet Francis | +61 3 9076 6564 | tms-trials@monash.edu |
Australia, Victoria | |
Monash Alfred Psychiatry Research Centre | Recruiting |
Melbourne, Victoria, Australia, 3004 | |
Contact: Jacqui Noonan +61 3 9076 6596 jacqui.noonan@monash.edu |
Principal Investigator: | Leo Chen, MBBS PhD FRANZCP | The Alfred |
Responsible Party: | Leo Chen, Head, Clinical TMS and Psychopharmacology Research Units, Monash Alfred Psychiatry Research Centre (MAPrc), The Alfred |
ClinicalTrials.gov Identifier: | NCT05591677 |
Other Study ID Numbers: |
567-22 |
First Posted: | October 24, 2022 Key Record Dates |
Last Update Posted: | January 22, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Depressive Disorder Depressive Disorder, Major Mood Disorders Mental Disorders Cycloserine Anti-Infective Agents, Urinary |
Anti-Infective Agents Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Antimetabolites Molecular Mechanisms of Pharmacological Action |